

**web:** <https://covidcirrhosis.web.unc.edu/>  
**email:** [covid.cirrhosis@unc.edu](mailto:covid.cirrhosis@unc.edu)  
**twitter:** @SecureCirrhosis


**web:** <https://covid-hep.net>  
**email:** [info@covid-hep.net](mailto:info@covid-hep.net)  
**twitter:** @COVIDHep

## Combined weekly update – 05 July 2020

We welcome you to this combined update from our two collaborating international registries: **SECURE-Cirrhosis** and **EASL supported COVID-Hep** collating clinical details of patients with chronic liver disease who develop COVID-19. *Please note that our registries contain predominantly hospitalised patients and are subject to reporting biases.*

### Total cohort (n = 904)

#### Submissions from 33 countries over 13 weeks



#### Characteristics

795 (88%) hospitalised  
576 (64%) men  
Median age 59 years (IQR 48-67)  
197 (22%) taking immunosuppressant drugs

#### Output

Chronic liver disease, JHep: [bit.ly/3bYxUy6](https://bit.ly/3bYxUy6)  
Liver transplant, Lancet G&H: [bit.ly/2Xmng01](https://bit.ly/2Xmng01)

### Chronic liver disease, non-cirrhotic (n = 339)

#### Major outcomes

Hospitalised	302	89%
Intensive care admission	66	19%
Invasive ventilation	62	18%
Death	27	8%

### Cirrhosis (n = 406)

#### Major aetiologies

Alcohol	125	31%
Non-alcoholic steatohepatitis	85	21%
Hepatitis C	44	11%
Hepatitis B	28	7%
Autoimmune hepatitis	23	6%
Alcohol & HCV	22	5%

#### Decompensation

Any	185	46%
New or worse ascites	110	27%
New or worse encephalopathy	107	26%
Variceal haemorrhage	15	4%

#### Major outcomes

Hospitalised	364	90%
Intensive care admission	111	27%
Invasive ventilation	72	18%
Death	133	33%

### Liver transplant (n = 159)

#### Major outcomes

Hospitalised	129	81%
Intensive care admission	47	30%
Invasive ventilation	31	20%
Death	30	19%

We look forward to providing more updates in future and soon hope to publish more definitive analyses of both our transplant and chronic liver disease cohorts. We would like to thank all contributors to both registries.